Scenarios that move WST
West Pharmaceutical Services, Inc. Common Stock
Scenarios that move WST: 25 analyses, 18 positive, 7 negative.
- · Ascendis Pharma receives positive CHMP opinion for TransCon CNP — ▲ · impact +9 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +33 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +28 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▼ · impact -18 · confidence low · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +6 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▼ · impact -13 · confidence low · horizon quarters
- · Bavarian Nordic raises 2026 outlook after strong Travel Health results — ▲ · impact +16 · confidence low · horizon quarters
- · BDX expands US manufacturing with $19B healthcare investment — ▼ · impact -25 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +12 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +4 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +8 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +8 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +45 · confidence low · horizon quarters
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +35 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +53 · confidence medium · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +8 · confidence low · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +14 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -18 · confidence low · horizon quarters
- · Beta Bionics stock plunges 37% after safety issues emerge — ▲ · impact +7 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +52 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▼ · impact -70 · confidence medium · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▲ · impact +9 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +30 · confidence low · horizon quarters
- · Beta Bionics prices public offering of stock and warrants — ▼ · impact -8 · confidence low · horizon quarters
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence medium